Good morning, everyone. Thank you for joining us. My name is Faisal Khurshid. I am one of the Senior Biotech Analysts at Jefferies. We are here in London at the Jefferies Global Healthcare Conference. Really pleased to have with us today management team of BeOne Medicines. I have on stage with me Aaron Rosenberg and Mark Lanasa. Aaron, can I pass it off to you for a quick introduction? Then we got a ton of topics to get into.
Sure. I am Aaron Rosenberg, the CFO of the company, along with Mark Lanasa, our solid tumor chief medical officer. Not marketing.
Yeah.
We are thrilled to be here. Look forward to a great discussion about the business.
Got it. Awesome. It is really great to have Dr. Lanasa here. Mark, can you just give us like a quick background on your role? I think that will provide context for really what we are going to spend most of the time talking about.
Sure. As you heard, my role is I am the Chief Medical Officer for solid tumors at BeOne. I have been here for almost five years now. I am a medical oncologist by training. My role is to oversee the end-to-end development of our growing solid tumor portfolio. It has been a really exciting year with multiple important data readouts. We have intentionally substantially grown our portfolio from having a, shall we say, predominant focus on immuno-oncology to having a much broader and more diversified portfolio of targeted therapies across lung, GI, and breast cancers.
Got it. Aaron, I would say, I mean, 2026, I think, has really felt like the year where the solid tumor portfolio has really come to life, with several programs moving into late stage. Mark, we are going to get into some of the science, some of the data, but before we get there, Aaron, can I just ask you to talk a little bit about, as you think about the evolution of BeOne Medicines, the kind of importance of the solid tumor franchise to the kind of long-term journey here?
Absolutely. The business has really been performing across the value chain. The company has gone through a series of inflection points in just the short time since I have been here. I joined in July 2024. Moving from a business with high growth, but shifting towards profit generation, establishing itself with its leading hematology franchise, BRUKINSA, solidifying its position as the leading BTKi in the class, generating more than $1 billion of revenue in the U.S. alone in Q3, $1.4 billion globally. The continued advancement of our hematology pipeline, BEQALZI, our next-generation BCL2 inhibitor, which is now approved for relapse refractory MCL in the U.S., as well as relapse refractory CLL in China. The advancement of our BTK degrader, which we talked about at our Q3 results, which met its objectives of its phase II trial, which could support potential accelerated submission mid-2027.
This year was certainly another inflection point as our solid tumor pipeline, we really focused on five key assets, but really, that is just the first wave of assets that we put into the clinic over the last two years, that all five assets we have read out really strong data sets at ASCO with our CDK4 and our B7-H4 ADC, with our PRMT5, GPC3, and our CEA ADC. All of those assets are moving, if not already started, in pivotal trials, but they are all moving toward those and have read out really significant data sets. This is another inflection point for the business, and we advance from a leading BTKi to a hematology franchise, and now, what is incredibly important, a multi-franchise oncology leading position. We are really excited about how the pipeline is shaping up.
Got it. Mark, can I put you on the spot, for these five kind of assets that you guys have profiled, that you've had data for this year, that you're moving into late-stage development, can I ask you to kind of like force rank, talk about your sort of level of excitement across the five?
Sure. We have excitement and belief in all five molecules, which is why we're taking them into pivotal study, but I appreciate the question.
Yes, sir. I know it's the pick your favorite kid question.
Yeah. No, no. I—
Make him answer it.
Yes. No, happy to do so. I will start with our GPC3 by 4-1BB, which is, in our belief, a first-in-class molecule for hepatocellular carcinoma, which has been a relatively neglected space. We have increasing confidence that this can be a transformational molecule for patients with liver cancer, which is not a rare disease. There are greater than 30,000 new cases a year in the U.S. It is the sixth leading cause of cancer mortality in the U.S. So, substantial unmet medical need. We just presented data at ESMO that our molecule as monotherapy at later line has a response rate of 35% confirmed response rate. This is with strong durability, greater than 70% six-month duration of response rate.
This compares very favorably to current standard of care, where the response rate is expected to be only about 5% with tyrosine kinase inhibitors, and has a very much favorable safety profile compared to the multi-targeted TKIs. From there, I would highlight our MTA cooperative PRMT5. Again, we just shared data at the ESMO Congress. It was a first disclosure, but a substantial disclosure. Our molecule is the most potent and selective inhibitor of PRMT5 that is under clinical investigation, based on our internal studies. Critically, our molecule was designed to be CNS penetrant. We think that this is a really important attribute, particularly for patients with non-small cell lung cancer, where, say, 40% of patients will develop CNS metastases at some point in their treatment journey.
The top line numbers, we had a confirmed response rate of 38%, which is the highest that has been reported with this mechanism to date. We had progression-free survival of 8.1 months, which really compares favorably to currently available therapies in second line or later non-small cell lung cancer. Critically, we had an intracranial response rate of 30%, which was consistent with our systemic response rates. We are very excited about the opportunities that are before us in non-small cell lung cancer. It will be starting combinations with daraxonrasib through our RevMed collaboration in pancreatic cancer any day. From there, I would highlight our CDK4 selective molecule. The core hypothesis there is that by having greater selectivity for CDK4 over six, you can dial down the CDK6-related hematologic toxicities that are dose-limiting and have deeper, more consistent coverage of CDK4. We presented at ASCO this year a 70% response rate.
We've started a phase III study with that molecule. We were very excited to share data at the recent ESMO for our CEA ADC, where again, we had a high confirmed response rate of 60% in patients with CEA-high non-small cell lung cancer, so it's biomarker selected, strong durability. I would also highlight our B7-H4 ADC, which has strong efficacy across breast and gynecologic cancers, has a very favorable safety profile compared to other molecules in class, and again, recently started its first phase III study in frontline ovarian cancer maintenance.
Got it. Thank you so much, Mark, for that overview. On GPC3, I like that you highlighted the size of the opportunity for HCC, because I think that's something that investors kind of underappreciate. Investors just, I think, aren't used to thinking about HCC.
Yeah.
As you mentioned, there hasn't been a lot of development. You mentioned at ESMO, you had some really nice data that you'd presented, but that data was generated primarily in Korea and China.
Yeah.
Where HCC is predominantly viral-driven. The U.S. population is a bit less viral-driven with HCC.
Yeah.
Can you just talk about whether that is a risk to translation of the data into a U.S. setting?
Yeah, it's a great question, so a couple things. One is I would start by saying that our development intent for all of our molecules is definitively global. I highlighted that the incident rate in the United States for HCC is over 30,000 cases a year. In China, it's over 300,000 cases a year. A bit of the enrollment that we've seen in the study is just driven by the global epidemiology, where it's more common in Asia, driven correctly, as you point out, by hepatitis B. It is a reasonable question of will we see consistent results across different etiologic subgroups of HCC. There's viral, hep B, hep C, and then non-viral, alcohol, and metabolic disorders. Importantly, we've characterized expression of GPC3 across these different subgroups.
Expression of GPC3 is really very consistent across viral and non-viral etiologies, and while it is a smaller subgroup of patients, we have seen responses now across all etiologic subgroups, including the non-viral subgroups, and across all regions. We have enrolled a fairly meaningful number of patients with frontline HCC to the combination of GPC3 by 4-1BB, our PD-1 tislelizumab, and bevacizumab. That is, again, a global cohort. We intend to share those first data at next year's ASCO meeting. We're excited about those data, and we think that they provide proof of concept and line of sight to a phase III study start in frontline disease.
Got it. With respect to the later line accelerated approval opportunity, I know you've enrolled the China cohort for that. Can you just give us a status update on the U.S. development in a late-line potential—
Yeah.
—accelerated approval setting?
This is a bit complex, as you highlight. There are actually three different studies that we are doing in later line to meet the needs of global regulatory authorities. First, we were able to expand our phase I study with a substantial cohort of patients in China and Korea that could provide a registration opportunity in those regions from that study. Through conversations with FDA, we are confident that the magnitude of improvement that we are seeing with our molecule could, if the data support, meet criteria for an accelerated approval. Therefore, we are actively starting a single-arm phase II study that will be a global study to support approval in the U.S. and potentially other regions such as Japan. Then third, we are starting a global randomized phase III study that will be GPC3 by 4-1BB monotherapy compared to investigator choice of available tyrosine kinase inhibitors.
Happy to announce that we actually achieved our global first patient enrolled overnight with that study, so that phase III is now also underway. So three different studies to achieve global access for this molecule in later line. Frontline is in a way more straightforward. We will have a single phase III study for all global regions.
Got it. I mean, amazing how fast this has kind of come to light, like in the, you see, in the last six months, right? I mean, this is a concept of 4-1BB co-stim bispecifics that has seen struggles, and you guys seem to have kind of cracked the nut here.
Thank you for that. With credit to our research and discovery organization, this was designed with certain attributes in mind. Our 4-1BB binder is unique. The relative affinity of GPC3 and 4-1BB was tailored to enable, should we say, predominantly conditional activation of 4-1BB when the molecule is in the presence of GPC3 expression. We think that those attributes have given us a favorable safety profile. The other detail is we have received the question of, well, why 4-1BB as the co-stimulatory molecule? This actually derives from other datasets that shows that by activating through 4-1BB, you get perhaps slower onset, but more continuous T-cell activation. We wanted to do that in patients with HCC because they tend to have medical comorbidities, believing that they would be better tolerated than, say, a CD3 conjugated T-cell engager.
Again, to the credit of the research organization, that is exactly how it has played out clinically.
Got it. I want to shift gears to PRMT5. I actually had in my head the order that I thought you were going to talk about these in. PRMT5, I did not have second in my head.
Okay.
I am curious that you mentioned that. Can you just confirm something? Investors have heard and appreciated your interest in lung cancer. Can you just talk about the extent to which you are interested in pancreatic cancer development? I think there has been some investor confusion there.
Yeah. So I understand that. I guess there's always the two sides of the coin. If you talk about something first, there's a question of why didn't you talk about the other thing first? The reason why we talk about non-small cell lung cancer, I talk about non-small cell lung cancer first, is again, because our molecule is designed to be CNS penetrant. That's why we emphasize non-small cell lung cancer in the early development program. Indeed, if you look across all of the clinical opportunities for an MTA cooperative PRMT5, lung cancer is, by a substantial margin, the largest addressable population. That said, we are absolutely committed to development in pancreatic cancer. We have enrolled patients with pancreatic cancer to monotherapy. We have already started enrolling patients to the combination of our PRMT5 inhibitor with current standard of care chemotherapies, such as gemcitabine and dose-modified FOLFIRINOX.
Critically, as I mentioned, we are imminently going to start a combination of our PRMT5 with daraxonrasib. So we're really excited about the opportunity that our recently announced collaboration with RevMed offers to us to advance in pancreatic cancer as well.
Got it. Then with respect to the CNS penetrance of the molecule, totally understand the importance of that in lung cancer, as you showed in the data at ESMO as well. When it comes to pancreatic cancer development, can you talk about whether there's any downside to having that CNS penetrance?
Yeah. So again, it is a great question. This is a bit of a, shall we say, a tricky area because there is feedback that we receive from investigators that is not, shall we say, completely published in the medical literature. But it is our understanding that precedent molecules, there have been, shall we say, what have been considered CNS toxicities. In the recent disclosure that we had at ESMO, we actually published explicitly our 20 most common AEs, so we could provide reassurance that we are not having any high-grade recurrent CNS toxicities associated with our molecule. So, we are very confident that the safety profile is developable across both tumor types that have and do not have frequent CNS metastases.
Again, not only in non-small cell lung cancer, but we think this characteristic opens up unique development opportunities, for example, in GBM, where we have already initiated a phase zero investigator-initiated trial.
Got it. Then, maybe just kind of double-clicking onto the RAS space while we are here. You guys have your own RAS(ON) inhibitor that is in phase I. Can you talk about that a little bit, and what should we expect there, and when we should see data?
Yeah. So I would start by saying that we are thrilled to have this collaboration agreement with Revolution Medicines. We are excited to have the opportunity to work with them, to commercialize in specific regions, to combine our portfolios, which we view as complementary. That said, there are some areas that we think are not yet fully addressed. So we have recently achieved a global first patient enrolled with our own RAS(ON) inhibitor. This molecule has very favorable PK characteristics based upon preclinical data, with a long half-life that should have relatively flat exposure. Again, critically, it was designed to have CNS penetrance, which is a unique and potentially beneficial characteristic, again, in non-small cell lung cancer. So we will be asking very specific clinical questions in our early dose escalation to see if there is residual unmet need that this molecule can address.
We're absolutely looking for a differentiated development path.
Got it. You guys have exceptional development capabilities. I think you call it the global development superhighway, right?
Superhighway. Yeah.
You have RAS(ON) on the highway now. Should we expect data next year?
From the RAS(ON)?
From our RAS( ON) molecule? I do not know yet, to give you an honest answer.
Typically, the life cycle of a phase I study, it is usually a year, maybe a little bit more until we have our initial data disclosure.
Got it.
But we're confident, sadly given the number of impacted patients, the residual unmet need, that that will progress quickly through early phase development.
Got it. I want to maybe skip over CDK4 and talk about your CEA ADC. I think that was also a very interesting piece of data that you had at ESMO. You mentioned something interesting to me at ESMO, that with the ability to do a biomarker-selective strategy and with the response rates that you're seeing, you may be able to look at an accelerated approval pathway here. Can you talk a little bit about that as well? Also on the molecule, right? I think this is the first ADC that's from your own in-house platform. Sorry, I know that was like four questions.
Oh, yeah. No, no. Thank you for that. Yes, notably, this is our first internally discovered ADC where we have proof of concept, so we're excited and proud of that. As I mentioned, we have a high response rate and strong durability. We think, again, in the context of what regulatory authorities are looking for single-arm conditional or accelerated approvals, a response rate that's unambiguously stronger than what's currently available, coupled with strong durability. In our view, that's what we have reported in the ESMO data. Now, we're still continuing to generate data, the so-called dose optimization phase. But if we think in aggregate, that total body of evidence is supportive, then we'll look forward to engaging the health authorities about the potential for an accelerated approval. We are committed to running a randomized later-line study that would also support global full approvals.
Got it. I know you're leading with lung cancer as well for this asset. But for the target, I believe there's a lot of expression in GI cancers like CRC as well.
There is.
Should we expect that to be an area that you go into?
Today, we do think the area of strongest differentiation is in non-small cell lung cancer, given the competitive landscape. But certainly, the door is open to exploration of other GI tumors or competitor molecules that are in phase III study in colorectal cancer. So we would want to have a differentiated data set there. And then there's also potential opportunity in gastric cancer, where a meaningful proportion of patients express CEA.
Got it. And then, actually, speaking of GI cancers, I wanted to go back to the RAS space. When you guys did the deal with RevMed, it was an interesting construction where you got daraxonrasib and regional rights, or not just daraxonrasib, the portfolio, I guess. And then in exchange, you run a global phase III study on RevMed's behalf. And then RevMed announced that that would be the frontline CRC study. Can you just talk to us about, to the extent you're able to, how that became the study chosen for you guys to run?
Sure. This speaks to the capability we have developed. You mentioned our global development superhighway. This is a broad-based collaboration where we can combine our assets with their broad portfolio. Mark spoke to both our PRMT5 as well as our EGFR MET by MET trispecific, as well as having a clinical supply arrangement where we can take those trials to their logical conclusion. You could look at, as part of our capabilities, we are running a global trial, as you said, in CRC. This is, you can think of as in consideration as part of the broader transaction, including our commercialization rights in select region, as Mark said. I think this is a broad-based arrangement, speaks to the capabilities that we brought to the table, and two companies with highly complementary portfolios.
Got it. Are you able to talk to why CRC was chosen?
Yeah, Mark.
I would just highlight it as an important indication for the RAS portfolio, and it was not related to, shall we say, a particular ability to deliver in that specific tumor type, but rather that was a next important phase III study that needed global delivery.
Got it. Okay. Yeah, that makes sense. Aaron, when you say Mark, when you are talking about the RevMed collab, you got to be clear which Mark we are talking about.
Oh, right.
I know we have had a really nice discussion on the solid tumor portfolio. We do have ASH coming up in a few weeks. I do not know which one of you wants to take the question, but—
Sure.
—I would love to just kind of hear if you can level set expectations of going into ASH. What should investors be looking out for? I know you have some exciting plenary session data coming up too.
Yeah. We're very excited about the upcoming ASH. We have our first plenary session, as you mentioned, for our MANGROVE data in the frontline in MCL, the first chemo-free regimen with the BTKi class, demonstrated a really strong PFS and a hazard ratio of 0.57x, so 43% risk reduction. Importantly, this is a space with MCL where BTKIs are historically under-penetrated. This is a really nice opportunity for patients in a disease with high unmet need, where we can really grow and expand our presence with BRUKINSA. BRUKINSA obviously has the broadest portfolio in the class. We've done really well across all five indications, and MANGROVE will provide an opportunity to continue to grow share in MCL. Beyond that, we have a number of exciting data readouts.
We have updates to our sonrotoclax plus zanubrutinib first-line trial, similarly with our BTK degrader, an update on the first-line trial there. We'll share some insights from our ramp-up schedule study associated with BEQALZI plus ZANU. We've talked a number of times about the challenges with the ramp-up associated with venetoclax and how that has under-penetrated the market, particularly in the community setting, and we're excited to share what we believe will be a differentiated ramp-up schedule for our combination and really encourage utilization in the broader sense.
Got it. Aaron, I really feel like 2026 has been the year for you guys of the solid tumor portfolio really coming to life. One, I'm curious, would you agree with that sentiment? How would you frame what you're expecting the story of 2027 to be?
I say yes and yes. I mean, I think the business is performing across all elements. Obviously, we've spent a lot of time, and we highlighted at the beginning of the year, how this year would be a bit of a coming out party associated with our solid tumor portfolio, and we've accomplished that through our updates at ASCO and ESMO, and there's much more to come. I'd be remiss not to mention how well the business is performing broadly. We continue to perform exceptionally well commercially, the leading BTK franchise continuing to drive strong financial performance, expand operating margins, deliver, which is translating to significant cash flow generation, more than $1 billion through the first three quarters of the year.
Yes, we're very pleased with how the solid tumor franchise is developing and the reception we've seen both with KOLs and with investors, and the potential that those therapies can bring for patients in the future. But we're equally as excited as to what our current portfolio is doing for patients in the marketplace today and how that's translating to strong financial performance.
Got it. Aaron, just to close us out, as you kind of increase the operating leverage and cash flow generation of the business, you guys have strongly built development capability that's also highly efficient. As you guys kind of generate more and more operating leverage, how should we think about capital allocation, like over the next few years, and does that continue to go into pipeline? Does BD, does share buyback come into this as well? How should we just think about the big picture? Any closing remarks you have as well would be great.
Sure. Our capital structure priorities are really unchanged. First and foremost, we'll continue to invest in our profit-making commercial franchises. We will invest in this incredible pipeline. We spent some time with our Q3 results just talking about the opportunity that's in front of us with our pipeline, and candidly, we still anticipate the ability as we move forward into 2027 to grow the bottom line and to modestly expand margins. But given all of that opportunity in front of us, we're going to make sure we maximize those assets. And that might translate to a little bit less margin expansion than we've seen, say, in 2026, where if you look at the midpoint of our guide, we're talking about like 1,000 basis points of margin expansion. Then we will continue to be active on business development.
It's been part of our DNA in partnerships, and really where we believe we can bring disproportionate value. That's leveraging our global development superhighway to bring innovative medicines to the market more quickly or with complementary assets. We have an incredible research organization, but we know there's a lot of science that happens out beyond our walls, and we're very engaged in that regard. Candidly, our balance sheet strength provides financial and strategic flexibility that we didn't have, say, two years ago. You mentioned return of capital to shareholders. I think that's something we will assess over time as we continue to strengthen the balance sheet, but at the moment, we're really focused on investing in our business.
Got it. Makes a lot of sense. Thank you so much, Aaron. Thank you, Mark, for being here. Really appreciate it.
Thank you.